Viatris Inc. is a global healthcare company that bridges the divide between generics and brands, aiming to provide access to medicines worldwide. The company's core business model focuses on manufacturing and distributing a diverse portfolio of medicines, including complex products, generics, and branded drugs. Viatris has a global supply chain and scientific expertise to address various health challenges. The company aims to deliver sustainable value to patients, shareholders, and customers. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India.

• Employees: Approximately 38,000
• Geographic Footprint: More than 165 countries and territories
• Headquarters: Canonsburg, Pennsylvania
• Founded: 2020 (through the combination of Mylan and Upjohn)
• Number of locations/facilities: Approximately 40 manufacturing sites
• Revenue: $15.43 billion (FY2023)
• Key Subsidiaries/Brands: Includes iconic and key brands and generics, including complex products

• CEO: Scott A. Smith
• CFO: Sanjeev Narula
• Chief Accounting Officer and Corporate Controller: Paul B. Campbell
• Board Chair: Melina Higgins

Key leaders have extensive experience in the pharmaceutical industry.

• Annual Revenue: $15.43 billion (FY2023)
• Net Income: $54.7 million (FY2023)
• Total Assets: $47.69 billion (as of December 31, 2023)
• Number of Employees: Approximately 38,000
• Key Financial Highlights: Revenue decreased by 5% year-over-year; net income decreased significantly due to various factors, including divestitures and restructuring costs.

Viatris offers a broad range of medicines across multiple therapeutic areas. Key categories include:

• Branded Drugs: Includes iconic brands and key global brands.
• Generic Drugs: Therapeutically equivalent versions of brand-name drugs.
• Complex Drugs: Medicines with complex active ingredients, formulations, or delivery systems.
• OTC Products: Over-the-counter products sold directly to consumers.

Viatris operates through four reportable segments:

• Developed Markets: Primarily in North America and Europe.
• Greater China: Includes operations in mainland China, Taiwan, and Hong Kong.
• JANZ: Includes operations in Japan, Australia, and New Zealand.
• Emerging Markets: Encompasses operations in more than 125 countries with developing markets and emerging economies, including the ARV franchise.

Revenue breakdown by segments is available in the financial statements.

Viatris is executing a two-phased strategic vision. Phase 1 focuses on stabilizing the base business, reducing debt, and returning capital to shareholders. Phase 2 involves moving up the value chain by focusing on more complex and innovative products. Key strategic initiatives include:

• Divesting non-core assets, including the OTC business, women's healthcare business, and API business in India.
• Investing in R&D for complex and novel products.
• Leveraging the Global Healthcare Gateway® to expand market reach.
• Focusing on three core therapeutic areas: ophthalmology, gastrointestinal, and dermatology.

Viatris operates in the highly competitive pharmaceutical industry. Key market trends include:

• Market Position: One of the largest providers of prescription medicines.
• Key Competitors: Faces competition from other generic and branded pharmaceutical manufacturers.
• Industry Trends: Pricing pressures, regulatory changes, and consolidation among customers.

• Strategic Risks: Uncertainties related to strategic initiatives, divestitures, and acquisitions; pricing pressures and consolidation in the supply chain.
• Operational Risks: Economic conditions, regulatory compliance, and supply chain disruptions.
• Financial Risks: Debt levels, currency fluctuations, and tax liabilities.
• Compliance Risks: Exposure to anti-corruption laws, intellectual property infringement, and cybersecurity threats.